In our cohort of patients with HR+/HER2- cancer, we found new AKT1 E17K alterations in 5% of patients in the BL cfDNA draw, 1% of patients in the 2nd draw, and 3% of patients in the 3rd draw. The gene discussed is AKT1; the disease is cancer.